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Transition state-based ST6Gal I inhibitors: Mimicking the phosphodiester linkage
with a triazole or carbamate through an enthalpy-entropy compensation
Abstract
Human β-galactoside α-2,6-sialyltransferase I (ST6Gal I) catalyses the synthesis of sialylated
glycoconjugates. Overexpression of ST6Gal I is observed in many cancers, where it promotes metastasis
through altered cell surface sialylation. A wide range of sialyltransferase inhibitors have been developed,
with analogues structurally similar to the transition state exhibiting the highest inhibitory activity. To
improve synthetic accessibility and pharmacokinetics of previously reported inhibitors, the replacement
of the charged phosphodiester linker with a potential neutral isostere such as a carbamate or a
1,2,3-triazole has been investigated. Extensive molecular dynamics simulations have demonstrated that
compounds with the alternate linkers could maintain key interactions with the human ST6Gal I active site,
demonstrating the potential of a carbamate or a 1,2,3-triazole as a phosphodiester isostere. Free energy
perturbation calculations provided energetic evidence suggesting that the carbamate and 1,2,3-triazole
were slightly more favourable than the phosphodiester. Further exploration with free energy component,
quasi-harmonic and cluster analysis suggested that there is an enthalpy-entropy compensation
accounting for the replacement of the flexible charged phosphodiester with a neutral and rigid isostere.
Overall, these simulations provide a strong rationale for the use of a carbamate or 1,2,3-triazole as a
phosphodiester isostere in the development of novel inhibitors of human ST6Gal I.
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Transition state-based ST6Gal
I inhibitors: Mimicking the
phosphodiester linkage with a
triazole or carbamate through an
enthalpy-entropy compensation
Andrew P. Montgomery1, Danielle Skropeta1,2,3 & Haibo Yu

1,2,3

Human β-galactoside α-2,6-sialyltransferase I (ST6Gal I) catalyses the synthesis of sialylated
glycoconjugates. Overexpression of ST6Gal I is observed in many cancers, where it promotes
metastasis through altered cell surface sialylation. A wide range of sialyltransferase inhibitors have
been developed, with analogues structurally similar to the transition state exhibiting the highest
inhibitory activity. To improve synthetic accessibility and pharmacokinetics of previously reported
inhibitors, the replacement of the charged phosphodiester linker with a potential neutral isostere such
as a carbamate or a 1,2,3-triazole has been investigated. Extensive molecular dynamics simulations
have demonstrated that compounds with the alternate linkers could maintain key interactions with
the human ST6Gal I active site, demonstrating the potential of a carbamate or a 1,2,3-triazole as a
phosphodiester isostere. Free energy perturbation calculations provided energetic evidence suggesting
that the carbamate and 1,2,3-triazole were slightly more favourable than the phosphodiester. Further
exploration with free energy component, quasi-harmonic and cluster analysis suggested that there is an
enthalpy-entropy compensation accounting for the replacement of the flexible charged phosphodiester
with a neutral and rigid isostere. Overall, these simulations provide a strong rationale for the use of
a carbamate or 1,2,3-triazole as a phosphodiester isostere in the development of novel inhibitors of
human ST6Gal I.
Sialic acid (N-acetylneuraminic acid, Neu5Ac) is one of the body’s most important sugars next to glucose1.
Sialylation, the addition of sialic acid to cell surface molecules via the glycosyltransferase (GT) enzymes known
as sialyltransferases (STs), is integral to cell function, governing numerous important biological processes including cell–cell recognition, protein targeting, cell adhesion, and fertilisation2–4. However, abnormal sialylation is
strongly associated with cancer, with hypersialylation of up to 30–40% seen in many cancers, along with marked
upregulation of ST activity. This has been directly correlated with an increased metastatic potential of tumours
and poor patient prognosis5,6. Upregulation of STs has also been shown to produce cellular resistance in both
paclitaxel and cisplatin treatment in human ovarian and colorectal cancer cell lines, along with reducing treatment efficacy7. Thus the critical role of STs in the process of tumour metastasis as well as drug resistance demonstrates that inhibitors of STs could be used either alone as anti-metastatic agents, or in combination with existing
drugs to enhance their sensitivity against resistant tumours8.
In humans, there are 20 different STs each of which share a common sugar nucleotide donor, cytidine
5ʹ-monophosphate Neu5Ac (CMP-Neu5Ac)2,9. STs are classified into one of four groups based on the position
and identity of the glycosyl acceptor (galactose, N-acetylgalactosamine or sialic acid) to which sialic acid is transferred: ST3Gal I-VI, ST6Gal I-II, ST6GalNAc I-VI, and ST8Sia I-VI2,3. Each ST subtype controls the synthesis

1

School of Chemistry, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW
2522, Australia. 2Centre for Medical and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522,
Australia. 3Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia. Correspondence and
requests for materials should be addressed to H.Y. (email: hyu@uow.edu.au)
SCieNtiFiC ReportS | 7: 14428 | DOI:10.1038/s41598-017-14560-0

1

www.nature.com/scientificreports/

Figure 1. Proposed reaction scheme for the catalytic mechanism of human ST6Gal I. R represents a glycan
chain of a glycoconjugate. Replicated from Montgomery, A., Szabo, R., Skropeta, D. & Yu, H. Computational
characterisation of the interactions between human ST6Gal I and transition-state analogue inhibitors: insights
for inhibitor design. J. Mol. Recogn 29, 210–222, doi:10.1002/jmr.2520 (2016) with permission from Wiley.

of specific sialylated structures with unique biological roles, therefore it is crucial that selective inhibitors are
developed.
Herein we focus on human β-galactoside α-2,6-sialyltransferase I (ST6Gal I), which is one of the two subfamilies of the ST6 family that belongs to the GT29 family (http://www.cazy.org)10. ST6Gal I catalyses the transfer of
a Neu5Ac residue to the 6ʹ-hydroxyl group of the terminal Gal residues of the disaccharide Galβ[1,4]GalNAc3,11.
ST6Gal I mediated sialylation can modulate protein conformation, oligomerisation and/or receptor internalisation12, depending on the substrate targeted. Overexpression of ST6Gal I is observed in several types of cancers
including lung, cervical, ovarian, pancreatic, breast and colon carcinoma13–16. It has been recently reported that
ST6Gal I promotes a cancer stem cell (CSC) phenotype, with the activity of ST6Gal I critical for CSC behaviours
including tumour spheroid growth, chemoresistance and tumour initiating potential16. Additionally, overexpression of ST6Gal I has been suggested to promote cancer cell metastasis through altered sialylation patterns affecting the function of β1 integrin17,18. ST6Gal I also has an important role in galectin regulation, via the sialylation
of their galactose-containing substrates12,13. For instance, α-2,6 sialylation of the galectin substrates Fas19 and
TNFR120 death receptors have been shown to hinder the apoptosis process, thus identifying ST6Gal I overexpression as an inhibitor of cell death pathways. It has also been recently demonstrated that ST6Gal I has a role in
promoting tumour cell survival within serum-depleted environments, such as those within the hypovascularised
regions of large, solid tumours21.
The catalytic mechanism of human ST6Gal I (Fig. 1) follows a classical SN2-like direct displacement mechanism for inverting GTs11,22. It is facilitated by the catalytic base His370, which promotes the nucleophilic attack on
the sialyl donor anomeric carbon by deprotonating the galactose 6ʹ-hydroxyl of the acceptor23,24. This generates
an oxocarbenium-like transition state (TS), followed by CMP acting as a leaving group. The β-configuration at
the anomeric carbon of the donor is inverted in the final product24. This is supported by a model of the Michaelis
complex generated from the glycan binding mode observed in the crystal structure of human ST6Gal I25.
The overexpression of ST6Gal I in various cancers has resulted in the development of a diverse range of ST
inhibitors26–28. Of these, analogues mimicking the proposed oxocarbenium ion-like TS of the donor (Fig. 1) exhibit
the highest affinity to STs29,30. TS analogue inhibitors incorporating a 2-deoxy-2,3-didehydro-N-acetylneuraminic
acid (Neu5Ac2en) moiety are amongst the most potent inhibitors. The TS-like characteristics are captured with
the C2-C3 double bond mimicking the planar anomeric carbon and an extra carbon between the anomeric carbon and CMP leaving group to mimic the elongated distance in the TS29,31. Various strategies have been adopted
to increase the potencies of these inhibitors. Derivatives which explore variations of the glycerol side chain of
the Neu5Ac2en moiety produced the greatest inhibitory activity. Of these, phenoxy derivative 1 (Fig. 2) is one of
the most potent TS analogue inhibitors reported to date (Ki = 29 nM for rat liver α-2,6-ST)32. More synthetically
assessable derivatives that incorporate an aryl replacement of the Neu5Ac2en moiety have comparable activity to
the phenoxy derivative 129,30,33. Of these the (R)-isomer of the phenoxy derivative 2 (Fig. 2) was a potent inhibitor of rat liver α-2,6-ST (Ki = 70 nM)29 and human ST6Gal I (Ki = 19 nM)34 and is the lead compound herein.
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Figure 2. Development of the phosphodiester-linked lead compound (2) and the analogous 1,2,3-triazole- (3)
and carbamate- (4) linked derivatives.

Recently, cyclopentyl34 and amide35 ST inhibitors have been reported with comparable nanomolar activity to the
phenoxy lead derivative (2) against human ST6Gal I.
Many of the above inhibitors were designed with limited knowledge of the target ST structure. The recent characterisation of the mammalian ST crystal structures, in particular that of human ST6Gal I25 and human ST8Sia
III36, has facilitated the use of computational modelling to aid in the design of new selective ST inhibitors. In this
work, we use computational modelling to investigate the effect of replacing the charged phosphodiester linkage
of TS analogue ST inhibitors. This is being investigated, as while contributing to potency37 the phosphodiester
linkage may potentially contribute to low bioavailability, loss of activity due to cleavage by phosphatases or instability in the ST active site38,39. To build upon our previous work40,41, molecular dynamics (MD) simulations and
binding free energy calculations via the free energy perturbation (FEP) method will be undertaken to investigate
the effect of replacing the phosphodiester linker of our lead compound 2, with either a 1,2,3-triazole (3; Fig. 2)
or carbamate (4; Fig. 2), has on binding to human ST6Gal I. Force field parameters compatible with the
CHARMM PARAM36 force field for the ligands will be developed42. Through equilibrium MD simulations the
conserved interactions as well as potential differences between each compound will be compared. Furthermore,
relative binding free energy calculations will be used to study the effect of the linker on binding affinity.

Methods

Force field development.

Force fields generated from the CHARMM General Force Field (CGenFF)43
using the paramchem interface (https://cgenff.paramchem.org) for the phosphodiester-linked 2 and the corresponding 1,2,3-triazole-linked 3 and carbamate-linked 4 derivatives (Fig. 2) were optimised using the GAAMP
method44. The partial atomic charges (see Supplementary Fig. S1 and Table S1) and identified “soft” dihedrals,
which were not already represented in the CHARMM and CGenFF force fields or that experienced a significant
penalty score from paramchem, were optimised (see Supplementary Fig. S2).

Molecular dynamics simulations. All MD simulations were prepared using VMD version 1.9.245. An
overview of all simulations is given in Supplementary Table S2. Simulation of human ST6Gal I (PDB id: 4JS2)–
inhibitor complexes with the reported phosphodiester-linked compound 2 and the proposed 1,2,3-triazole
and carbamate-linked derivatives (3 and 4 respectively; Fig. 2) were undertaken to determine if a carbamate
or 1,2,3-triazole is a suitable replacement for the phosphodiester linker used in previously reported inhibitors.
The initial structure for the ST6Gal I–inhibitor complexes was taken from previously reported docking studies40. Additionally, simulations of each inhibitor in a water box were also performed to determine the effect of
linker flexibility. Prior to simulation being undertaken PROPKA 3.146 was used to predict the protonation state of
ST6Gal I residues and ionisable ligand groups at pH 7.0.
Preparation of each simulation involved solvating the system in a box of water molecules, which extended
approximately 9 Å from the surface of the protein, resulting in each system being solvated in an 82 Å × 82 Å × 82 Å
cubic TIP3P47 water box. Each box was neutralised with counter ions of Na+ and Cl−, with the salt (NaCl) concentration set to 0.15 mol/L. Simulations were carried out using the NAMD 2.9 package48. The protein was represented with the non-polarisable CHARMM PARAM36 force field49. The force field for each ligand were those
optimised using the GAAMP method44. All systems were simulated in periodic boundary conditions using
the Langevin algorithm for maintaining the temperature at 298.15 K, and the Langevin Piston Nose–Hoover
method50,51 for maintaining a constant pressure of 1.0 bar. The electrostatic interactions were calculated using the
Particle Mesh Ewald method52. The van der Waals forces were treated with a cut-off of 12 Å and a smoothening
function between 10 and 12 Å. All of the covalent bonds involving hydrogen were kept rigid with the RATTLE
algorithm53. The integration time step was set to 1.0 fs, 2.0 fs and 4.0 fs for bonded, non-bonded and long-range
electrostatics, respectively.
Equilibrium simulations for all human ST6Gal I-inhibitor complex systems were initially undertaken. During
these simulations, a harmonic restraint was placed upon all Cα atoms of human ST6Gal I, with a decreasing
SCieNtiFiC ReportS | 7: 14428 | DOI:10.1038/s41598-017-14560-0
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Figure 3. The thermodynamic cycle used (a) and a schematic representation of the perturbation performed (b)
in the phosphodiester to carbamate FEP calculations. Phos and the yellow circle represent the phosphodiesterlinked lead compound (R)-2, Carb and the red square represent the carbamate-linked derivative (R)-4, and E
represents human ST6Gal I.

force constant from 32.0 to 1.0 kcal/mol/Å2 over 10 ns. This decrease was achieved gradually by halving the force
constant for each respective 1 ns interval until a force constant of 1.0 kcal/mol/Å2 was obtained (i.e. 32.0, 16.0
… 1.0 kcal/mol/Å2). A force constant of 1.0 kcal/mol/Å2 was then applied for the remainder of the 10 ns thermal equilibration. The simulations were further continued for 90 ns without any restraints (see Supplementary
Table S2). The inhibitor only simulations (see Supplementary Table S2) were performed for 20 ns with a harmonic
restraint placed upon one atom of the corresponding ligand, with a force constant of 32 kcal/mol/Å2. To perform
trajectory analysis, snapshots were saved every ps (i.e. every 1,000 steps). Replicates of each simulation from
different starting coordinates were generated by starting each simulation with three different initial minimisation
steps (i.e. 2,000, 2,500 and 3,000 steps) and initiated with different velocities. In total, 2.2 μs of MD simulations
were performed.

Simulation trajectory analysis. To monitor the global properties of the structural evolution during MD
simulations, the atomic positional root-mean-square deviations (RMSD) with respect to a reference structure and
the atomic positional root-mean-square fluctuations (RMSF) were calculated using VMD45.
Hydrogen bond interactions were analysed according to a geometric criterion. A hydrogen bond was defined
by a minimum donor–hydrogen–acceptor angle of 120° and a maximum heavy atom distance of 3 Å. Hydrophobic
contacts were also analysed according to a geometric criterion of a maximum distance of 4 Å between hydrophobic atom pairs. To identify these interactions CHARMM version 38a154 was utilised.
The quasi-harmonic approximation55–57 was used to examine the loss of configurational entropy of each
ligand upon binding to human ST6Gal I. This analysis was performed, using CHARMM version 38a154, for trajectories encompassing 11–100 ns (11–55 ns and 56–100 ns were also performed to monitor convergence; See
Supplementary Table S3) of each ligand in complex with human ST6Gal I and trajectories encompassing 1–20 ns
(1–10 ns and 11–20 ns were also performed to monitor convergence; See Supplementary Table S3) of the ligand
simulations. Prior to the analysis, the Cartesian coordinates of the ligands were aligned after least-squares fit
superposition of the heavy atoms of all configurations onto the initial structure, to eliminate the overall translation and rotation. The change in configurational entropy (ΔS conf ) was determined based on the following
relationship:
ΔSconf = S(complex) − S(free) .

(1)

Using the structures obtained from the MD simulations, conformational cluster analysis was performed for
the ligands using MMTSB tools58. Clusters were identified using k-means clustering with an RMSD threshold for
ligand heavy atoms of 1.6 Å. For each simulation, cluster analysis was based on combined trajectories of every
10 ps of triplicate simulations. This resulted in 27,000 structures used in the analysis of the complexed simulations
and 6,000 structures for the ligand only simulations.

Free energy perturbation calculations. All free-energy perturbation (FEP) calculations described
herein were carried out using the NAMD 2.10 package48. The simulation parameters were as per the MD simulation method described above. Depending on the calculation the starting structure was taken from the ST6Gal
I-inhibitor simulations of the (R)-diastereomers of either the phosphodiester-linked lead compound (R)-2
or the carbamate-linked derivative (R)-4 and temperature was maintained at either 288.15 K or 298.15 K (see
Supplementary Table S2).
Each calculation utilised a dual ligand approach, where a ligand is mutated to an analogue in the human
ST6Gal I binding site and the reverse mutation is performed simultaneously on the analogue in bulk water in the
same system (Fig. 3). This approach has been undertaken to minimise potential electrostatic finite-size effects
posed by the change in charge state when the (R)-diastereomer of the phosphodiester-linked lead compound
2 (net charge of -2e) is perturbed to the (R)-diastereomer of either the 1,2,3-triazole- 3 or carbamate-linked 4
derivatives (net charge of -1e) (Fig. 3)59,60. In this approach, the overall charge of the system remains constant.
This allows for the reduction of errors arising from the large solvation energy of charged ligands and potential
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artefacts from the use of periodic boundary conditions. A similar approach has been successfully employed to
handle changes in charge state in several different biomolecular systems61.
Using the dual ligand approach, the change in the binding free energy due to linker mutation with perturbation from phosphodiester to carbamate as an example can be expressed as (Fig. 3)
ΔΔG b = ΔGCb –ΔGPb
= ΔG2–ΔG1
= ΔΔGex
= Σi ΔΔGex, i

(2)

In the FEP method, one introduces a hybrid Hamiltonian, H(λ) = (1 − λ)H0 + λH1, where H0 represents the
Hamiltonian for the initial state and H1 for the final state. The interval between 0 and 1 is divided into n subintervals (λi, where i = 1, …, n – 1), and for each subinterval the free energy difference is calculated from the ensemble
average, ΔΔGex,i = −kBT ln < exp[−(H(λi+1) − H(λi))/kBT > λi. The free energy difference between initial and
final states is obtained from the sum, ΔΔG = Σi ΔΔGex,i. Alchemical transformations were carried out with 20
uniformly distributed λ values between 0 and 1 (0.0, 0.05, 0.1, …, 0.9, 0.95, 1.0), with the transformation simulated in reverse directions beginning from the 0.×5 λ values (e.g. 0.0 ← 0.05 → 0.1). To prevent the occurrence
of singularities at values of λ where an atom disappears/appears, a soft-core potential with α = 4.0 Å2 was used to
reshape the Lennard-Jones potential into a form devoid of singularity when λ approaches either 0 or 162,63.
Each λ window underwent initial 5000 energy minimisation steps followed by 1 ns equilibration simulation
to provide starting coordinates. Each window was then subsequently simulated for multiple ns with a harmonic
restraint placed on the centre of mass of ST6Gal I. A harmonic restraint was also applied to one atom from the ligand
in the bulk. These restraints were applied to prevent association of the ligand in the bulk and ST6Gal I and had no
effects on the calculated binding free energy difference. Both restraints used a force constant of 32 kcal/mol/Å2.
In total 1.02 μs of FEP simulations were performed.

Results and Discussion

1,2,3-Triazole- and carbamate-linked (R)- and (S)-diastereoisomers maintain consistent binding
site contacts with human ST6Gal I when compared to their phosphodiester derivative.

Hydrogen bond and hydrophobic contact analysis of phosphodiester- and carbamate-linked (R)-diastereomers
has previously been published40. These simulations were performed using ligand force fields generated using
the general AMBER force field (GAFF)64 and with human ST6Gal I represented with the non-polarisable
CHARMM PARAM36 force field49. In this work, a force field parameterisation compatible with the CHARMM
PARAM36 force field was carried out for the ligands. We have undertaken simulation of both the (R)- and
(S)-diastereoisomers of the phosphodiester- (2), 1,2,3-triazole- (3) and carbamate-linked (4) derivatives (Fig. 2)
in complex with human ST6Gal I with the newly developed force field.
The MD simulations of each complex showed a stable trajectory with the positional RMSD of backbone Cα
atoms being 1.5–2.0 Å for each simulation (see Supplementary Figs S3–S8). RMSFs for the Cα atoms, were generally consistent across all simulations (see Supplementary Figs S3–S8). Larger RMSF values, across each simulation, were observed for the flexible loop between Tyr355 and Tyr369. Large RMSF values were also observed
for the regions between Gln235—Asn250 and Ser260—Ile295, which comprise the portion of the active site that
is expected to interact with the sialyl acceptor. This can most likely be attributed to the phenoxy being within
the proposed sialyl acceptor site. Across all simulations each ligand remained tightly associated with the human
ST6Gal I active site. However, there was some variation in ligand position within this active site, which can be
seen in the RMSD values that correspond to the heavy atoms of each ligand (see Supplementary Figs S3–S8).
These fluctuations can be attributed to the m-phenoxy substituent, which depending upon the simulation either
rotated to maintain contacts with the sialyl acceptor site or only weakly interacted with peripheral residues of this
pocket, resulting in positional fluctuation.
Interactions in the human ST6Gal I-ligand complexes analysed were characterised by monitoring the hydrogen bonds and hydrophobic contacts (see Supplementary Tables S4–S15). Each simulation revealed similar interactions with the ST6Gal I active site, which have been schematically illustrated in Fig. 4.
The cytidine moiety of each simulation’s respective compound maintained the hydrogen bonding interactions
that were observed in the human ST6Gal I crystal structure25. An additional interaction observed in all simulations was Lys376 acting as a hydrogen bond donor to the pyridine like nitrogen of the cytosine ring. There was
also Ser189 acting as a hydrogen bond donor with the oxygen embedded within the furan ring in the simulations
of the (S)-diastereomers (Fig. 4b). The hydrophobic contacts that were observed were most significant with the
cytosine ring, which was shown to interact with Ala190 and have a proposed π-stacking interaction with Tyr354.
The ribose ring was generally shown to have hydrophobic interactions with Phe211 and Leu372. It should be
noted that in the simulations of the (R)-diastereomers only (Fig. 4a), a water bridge interaction between the free
amine of the cytosine ring and the backbone carbonyl of Val352 was also observed.
In addition to the CMP moiety, each compound had two other conserved regions, the phosphonate and the
Neu5Ac mimic. For the simulation involving the (R)-diastereomers the phosphonate was shown to hydrogen
bond with His370 in all simulations and, Ala368 and Tyr369 in all simulations except TC1 (see Supplementary
Table S8). The phosphonate in the simulations of the (S)-diastereomers occupied a different orientation within
the ST6Gal I active site and was shown to hydrogen bond with Tyr354 in all simulations. This difference between
the diastereomers is to be expected as the phosphonate is a substituent at the only varied chiral centre. This could
also be an explanation to the higher level of potency observed for (R)-2 compared to (S)-2 when tested against rat
α-2,6 ST29, which has been shown to have a high level of homology to the human equivalent23.
SCieNtiFiC ReportS | 7: 14428 | DOI:10.1038/s41598-017-14560-0
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Figure 4. Schematic representation of conserved hydrogen bonds and hydrophobic contacts observed in the
(R)-diastereomer- (a) and (S)-diastereomer-ST6Gal I complex (b) simulations. The consistent components of
each inhibitor are shown as chemical structures. The orange box represents the different linkers. Interacting
human ST6Gal I residues are represented as circles which are colour coded based on interaction type as
follows: Red = hydrogen bond donor; Green = hydrogen bond acceptor; Blue = water bridged hydrogen
bond; Grey = hydrophobic contact; Pink = hydrogen bond and hydrophobic contact. Dashed lines indicate
hydrophobic contacts and dotted lines represent the hydrogen bonds shown in Supplementary Tables S4–S15.

The Neu5Ac mimic consists of two components, the aryl ring and its m-phenoxy substituent. The m-phenoxy
substituent for the majority of the simulations was shown to be in, or oriented towards, the proposed sialyl acceptor site through observed hydrophobic contacts with Asn233, Gln235, Trp257, Pro259, Tyr275 and Tyr369.
This was most evident for the (S)-diastereomers. More variation in this group’s position was observed for the
(R)-diastereomers, with the phenoxy generally orientated to interact only with the residues on the periphery of
the pocket, being Asn233, Tyr369 and His370. Notably of the three different classes of linker observed, it was
the 1,2,3-triazole that showed both the (R)- and (S)-diastereomers with the same m-phenoxy interactions (see
Supplementary Tables S9 and S11), suggesting the added rigidity of the linker favours direction towards the proposed sialyl acceptor site. This is an important finding, as this site is expected to vary between the different ST
subtypes, particularly those with different sialyl acceptors, and thus presents a potential route to the development
of selective human ST6Gal I inhibitors.
The aryl ring of the Neu5Ac mimic was shown to have limited interactions with human ST6Gal I, with the
(R)-diastereomers showing hydrophobic contacts with Tyr369 and His370 and the (S)-diastereomers with
Leu236. Despite being limited these interactions are nevertheless important in directing the m-phenoxy towards
the proposed sialyl acceptor site. This is clearly highlighted in the CL2 simulations (see Supplementary Table S2)
where this aryl ring is shown to interact with Cys353, Tyr354 and Cys364 in a binding mode that does not see the
m-phenoxy within the proposed sialyl acceptor site.

SCieNtiFiC ReportS | 7: 14428 | DOI:10.1038/s41598-017-14560-0

6

www.nature.com/scientificreports/
ΔΔGb

ΔΔHbc

−TΔΔSbc

—

—

Alchemical
Transformation

288 K

2→4

−1.1 ± 0.8 −1.7 ± 0.4 10 ± 30

−20 ± 30

2→3

−0.3 ± 0.3 −1.4 ± 0.9 40 ± 30

−40 ± 30

4→3

−0.7 ± 1.0 −0.5 ± 0.3 −10 ± 30

10 ± 30

a

298 K

b

Table 1. Difference in binding free energy to human ST6Gal I of proposed ST inhibitors. Running average of
ΔΔGb (kcal/mol) calculated at a288.15 K and b298.15 K, error reported is the SEM. cThe ΔΔHb (kcal/mol) and
−TΔΔSb (kcal/mol) are calculated through finite-temperature difference from the ΔΔGb values for both the
simulations carried out at 288.15 K and 298.15 K. The values reported are those for 298.15 K, error reported is
the SEM.

The only component of the potential ST inhibitors examined that varied was the group that links the CMP
moiety to the Neu5Ac mimic. Consistent interactions were observed when comparing the phosphodiester linker
to the 1,2,3-triazole- and carbamate linkers. In the simulations of the (R)-diastereomers, hydrogen bonds of the
linkers with Asn212 and Tyr354 were observed. In the simulations of the (S)-diastereomers hydrogen bonds of
the linkers with Asn212 were observed.
Analysis of the hydrogen bond and hydrophobic contacts of both the (R)- and (S)-diastereomers of the three
different classes of compounds, has demonstrated that no matter which linker is used, key interactions of cytidine
and the Neu5Ac mimic with the human ST6Gal I active site are able to be maintained. These results confirm our
previous findings40 and provide further evidence that a carbamate or a 1,2,3-triazole may be a suitable isosteric
replacement for the phosphodiester linkers that have been used in reported ST inhibitors.

Binding free energy calculations confirm 1,2,3-triazole and carbamate as isosteres of the phosphodiester linker. To build upon the results observed in the MD simulations on the thermodynamic level,

FEP calculations were performed to study the relative binding affinities for compounds with three different linkers. These simulations involved the alchemical transformations of the phosphodiester-linked (R)-2 to either the
1,2,3-triazole (R)-3 or carbamate-linked (R)-4 derivatives. To close the thermodynamic cycle in order to monitor
the convergence, an additional transformation of the carbamate-linked (R)-4 to the 1,2,3-triazole-linked (R)-3
was also performed. The results of the FEP calculations are summarised in Table 1.
The ΔΔGb values observed for the 288 K and 298 K calculations form a thermodynamic cycle which closes
within a reasonable error of −1.5 kcal/mol and −0.8 kcal/mol respectively. These calculations indicate that there
is only a slight difference in the free energy of binding between the carbamate- and 1,2,3-triazole-linked derivatives, with the 1,2,3-triazole favoured. It was also demonstrated that when the phosphodiester linker of the lead
compound is perturbed to either a carbamate or a 1,2,3-triazole, a slightly more favourable binding to ST6Gal I
is observed (−1.7 kcal/mol and −1.4 kcal/mol respectively at 298.15 K), with the carbamate being slightly more
preferential.
This result is surprising as the charge of the phosphodiester linker has been previously thought to be important for binding, but to what extent is currently unknown29,32,34,35,38. It is expected that replacing the charged
phosphodiester group with a neutral isostere could potentially result in the loss of favourable interactions with the
binding site that are mediated by this charge. For example, in the MD simulations the phosphodiester linker was
involved in three additional water mediated interactions that were not observed in those of the carbamate- and
1,2,3-triazole-linked derivatives (see Supplementary Tables S4, S8, S12). Therefore, one would expect an impact
on the binding free energy (ΔGb), particularly through enthalpy (ΔHb), if the charged phosphodiester linker
were to be replaced. Based on the relatively similar binding free energies for compounds with three different
linkers, we hypothesise that the more rigid isosteric linkers might achieve comparable binding affinities through
a favourable entropy compensation.
The error analyses for the FEP simulations were carried out by calculated the standard error of the mean
(SEM) based on each ns simulation segment (Table 1) and all simulations converged with an error of <1.0 kcal/
mol. RMSD of both protein backbone and complexed ligand were also monitored. RMSDs for Cα of ST6Gal I
converged between 1.5 Å and 2.0 Å indicating that no significant change in the structure of the protein backbone
occurred as one linker was perturbed to another. Across all simulations each ligand remained tightly associated
with the ST6Gal I active site, with RMSD values that fluctuated between 1.0 Å and 3.0 Å observed. As with the
MD simulations discussed above, this fluctuation was influenced by the m-phenoxy substituent, with it remaining
fixed in the sialyl acceptor site for the lower RMSDs observed and with it orientated towards the sialyl acceptor
site but not constantly located within it when larger RMSDs were observed.

Relative rigidity of the 1,2,3-triazole and carbamate linkers compensate for the enthalpic
penalty that results from replacing the phosphodiester. To test our enthalpy-entropy compensa-

tion hypothesis proposed based on the FEP calculations, we calculated ΔΔHb and ΔΔSb from the ΔΔGb values observed at two different temperatures (Table 1)65. From this analysis, we were able to demonstrate that
the replacement of the charged phosphodiester linker with either a neutral carbamate or 1,2,3-triazole indeed
results in an enthalpic penalty (a positive ΔΔHb). In both cases this penalty was compensated for by a favourable
entropy (a negative ΔΔSb). This supports our hypothesis of the resulting molecular rigidity created by the inclusion of a carbamate or 1,2,3-triazole in place of a phosphodiester compensates for the enthalpic penalty. For the

SCieNtiFiC ReportS | 7: 14428 | DOI:10.1038/s41598-017-14560-0

7

www.nature.com/scientificreports/
Cpd

ΔSconf (kcal/mol/K)a

−TΔSconf (kcal/mol)b

(R)-2

−0.125 ± 0.009

37 ± 3

(S)-2

−0.14 ± 0.02

41 ± 6

(R)-3

−0.08 ± 0.01

23 ± 4

(S)-3

−0.09 ± 0.01

27 ± 4

(R)-4

−0.067 ± 0.007

20 ± 2

(S)-4

−0.09 ± 0.02

25 ± 6

Table 2. Configurational entropy change upon binding of phosphodiester-linked (2), 1,2,3-triazole-linked
(3) and carbamate-linked (4) derivatives to human ST6Gal I. aArithmetic mean ΔSconf ± standard error of the
mean (SEM) obtained from triplicate simulations of each compound. bArithmetic mean ΔSconf multiplied by
−298.15 K ± SEM obtained from triplicate simulations of each compound.

perturbation from the carbamate to the 1,2,3-triazole, the opposite relationship was observed where changing to
a triazole was enthalpically favourable which compensated for an entropic penalty.
The effect of the entropic component of binding free energy to human ST6Gal I has also been demonstrated
through quasi-harmonic analysis of the trajectories obtained from the MD simulations performed (Table 2). This
analysis has shown that for both the (R)- and (S)-diastereomers, the phosphodiester-linked lead compound 2 has
a larger configurational entropy penalty upon binding to human ST6Gal I when compared to the 1,2,3-triazole3 and carbamate-linked 4 derivatives. Though the quasi-harmonic analysis only captures the configurational
entropy of the ligands upon binding, while neglecting contributions from other factors, the relatively large difference observed supports the entropic compensation that was captured in the component analysis of the ΔΔGb values (Table 1). It can also be seen that there is comparatively a very small difference (that is within error) between
the −TΔSconf values for the carbamate and 1,2,3-triazole (Table 2). However, the 1,2,3-triazole does exhibit a
slightly larger value for both the (R)- and (S)-diastereomers supporting the entropic penalty observed when a
carbamate is perturbed to a 1,2,3-triazole (Table 1).
Comparing the diastereomers it can be seen while there are no major differences between the diastereomers,
the (S)-diastereomer in all three cases has a slightly larger entropic penalty for binding to ST6Gal I. This result
reflects the slight differences in the binding modes of the diastereomers observed during the analysis of the MD
simulations.
Overall both the free energy component analysis and the quasi-harmonic analysis have demonstrated that
the conformational restriction, and thus entropic favourability for binding, imparted by the 1,2,3-triazole and
carbamate linkers when compared to the phosphodiester linker is enough to compensate the resulting enthalpic
penalty. This result has provided a strong rationale for the use of these two groups as isosteres of the phosphodiester in the development of potential inhibitors of human ST6Gal I. Interestingly, while we have demonstrated the
benefit of introducing conformational restriction to binding, there appears to be a limit to what can be tolerated.
This is reflected in the carbamate being shown to be slightly more entropically favourable than the 1,2,3-triazole
(Tables 1 and 2).

Conformational cluster analysis demonstrates different linker flexibilities. Additional clustering

analysis was performed for the ligand conformations in the human ST6Gal I-ligand complex and in the aqueous
solution. The most dominant cluster for each complex simulation (see Supplementary Fig. S9) showed similar
positions for the cytidine and phenoxy substituents for both the (R)- and (S)-diastereomers. This supports the
findings of the analysis of the protein-ligand interactions (Fig. 4). The conformations of these structures also
provide an indication of the differing levels of flexibility of each linker, with the conformation of the 1,2,3-triazole
derivatives being much more rigid and elongated when compared to the phosphodiester- and carbamate-linked
counterparts. However, this conformational difference is much more obvious in the distribution of cluster population obtained from the ligand in water box simulations (see Supplementary Fig. S10). The distribution for the
(R)-diastereomers shows the phosphodiester-linked ligand samples a much larger conformational space than
both its carbamate- and 1,2,3-triazole-linked counterparts, as evidenced by the number of clusters identified. The
distribution for the (S)-diastereomers shows a similar trend, however the difference between the phosphodiester
and carbamate derivatives is not as large. The increased flexibility of the phosphodiester derivatives compared to
the 1,2,3-triazole- and carbamate-linked derivatives provides further evidence to support the enthalpy-entropy
compensation hypothesis.
It is worth noting that though the binding free energy differences are converged within 1.0 kcal/mol, a proper
error propagation significantly increases the uncertainties in the enthalpic component (ΔΔHb) and entropic
component (−TΔΔSb) (Table 1). Nevertheless, our calculations have demonstrated that these three types of
inhibitors with different linkers have similar potencies against human ST6Gal I. Complementary analyses based
on binding entropy calculations, quasi-harmonic and conformational cluster analyses highlighted the potential
role of entropy in the binding of transition state-based ST6Gal I inhibitors. Experimentally, we are synthesising both the 1,2,3-triazole- and carbamate-linked derivatives and their predicted potency will be validated with
experimental inhibition rates and kinetic constants. The enthalpy-entropy compensation hypothesis can be then
validated by examining the temperature-dependent data.
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Conclusion

MD simulations and FEP calculations were performed to investigate the replacement of the charged phosphodiester linker used in reported TS analogue ST inhibitors with a neutral isostere, such as a carbamate or a
1,2,3-triazole. MD simulations of the (R)- and (S)-diastereomers of three ligands, which only differed in the linker,
complexed with human ST6Gal I or in a water box were performed. Hydrogen bonds and hydrophobic contacts
of the ligands with human ST6Gal I were monitored over the course of the simulations and have demonstrated
that no matter which linker is used, important interactions with the active site are able to be maintained. These
results confirmed the findings of our previous work40, which was undertaken with a different set of force fields.
Free energy perturbation calculations demonstrated that when the phosphodiester linker was perturbed to either
a carbamate or a 1,2,3-triazole a slightly more favourable binding to human ST6Gal I was observed, with the carbamate being marginally more preferential. This result was a surprise considering the perceived importance of the
phosphodiester linker. We rationalise this observation with a hypothesis of an enthalpy-entropy compensation,
which is supported with free energy component analysis, quasi-harmonic and cluster analysis. These analyses
demonstrated that the conformational restriction, and thus entropic favourability for binding, imparted by the
1,2,3-triazole and carbamate linkers when compared to the phosphodiester linker is enough to compensate the
resulting enthalpic penalty. The results of these simulations have provided a strong rationale for the use of a carbamate or 1,2,3-triazole as an isostere of the phosphodiester. We are currently exploring both potential isosteres
synthetically with the aim to develop novel inhibitors of human ST6Gal I, improve synthetic accessibility and
address potential pharmacokinetic problems.
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